Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
- Rutger Schepp; Joanna Kaczorowska; Pieter van Gageldonk; Elsbeth Rouers; Elisabeth Sanders; Patricia Bruijning-Verhagen
Access Resources
About
This article describes a study about using palivizumab to prevent RSV infections. It focuses on very preterm infants during their first year. The research took place in the Netherlands and aimed to see if this treatment could lower infection rates. The article concludes that palivizumab reduces RSV infection in very premature infants, but future research should look at clinical implications and reasons for non-compliance, and compare palivizumab with emerging prophylactics like nirsevimab.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.